Biogen Inc.

BIIB

US09062X1037

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.

Employees

7,570

Sector

Pharmaceuticals

Calendar

2025-01-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

income-statement-evolution-chart BIOGEN-INC

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

157.78USD

Average target price

253.83USD

Spread / Average Target

+60.88%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 16:00:00 2024-12-06 EST			5-day change	1st Jan Change
157.78 ^USD	-0.93%		-1.77%	-39.03%

12-06	Glaxosmithkline in collaboration with Muna Therapeutics on Alzheimer's disease	FW
12-05	Morgan Stanley Adjusts Price Target on Biogen to $192 From $204, Maintains Equalweight Rating	MT

Glaxosmithkline in collaboration with Muna Therapeutics on Alzheimer's disease	12-06	FW
Morgan Stanley Adjusts Price Target on Biogen to $192 From $204, Maintains Equalweight Rating	12-05	MT
Biogen Says Leqembi Got Approval to Treat Early Alzheimer's Disease in Mexico	12-05	MT
Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" for the Treatment of Early Alzheimer's Disease in Mexico	12-04	CI
Biogen Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-03-2024 09:10 AM	12-03
Biogen, Eisai Launch Alzheimer's Drug Leqembi in South Korea	11-29	MT
Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" for the Treatment of Alzheimer's Disease Launched in South Korea	11-27	CI
Cassana Sciences collapsed after study disappointment in Alzheimer's	11-26	FW
BIOGEN : Jefferies confirms its target as it awaits Ocrevus	11-25	CF
European Commission Approves Samsung Bioepis, Biogen's Biosimilar Opuviz	11-20	MT
Mizuho Securities Adjusts Price Target on Biogen to $207 From $251	11-20	MT
Biogen, Partner Say Late-Stage Trial of Lupus Erythematosus Drug Candidate Met Primary Endpoint	11-19	MT
UCB: positive phase 3 results in lupus	11-19	CF
Biogen: positive phase 3 results in lupus	11-19	CF
Quiet before the earnings quake	11-18
Needham Downgrades Biogen to Hold From Buy	11-18	MT
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ	11-18	CI
Analyst recommendations: Biogen, HP, Moderna, Shell...	11-18
Needham Downgrades Biogen to Hold From Buy	11-18	MT
Baird Raises Biogen Price Target to $300 From $294, Maintains Outperform Rating	11-15	MT
Biogen's Alzheimer's Disease Drug Gets Positive Opinion From Europe Regulators	11-14	MT
Biogen, Eisai Win CHMP Backing of Leqembi Alzheimer's Drug	11-14	DJ
Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer?s Disease	11-14	CI
Argus Cuts Biogen's Price Target to $200 From $250	11-05	MT
Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA	11-01	MT

Biogen Inc.

Equities